Clinical pharmacology of thalidomide (original) (raw)

Pharmacological Properties of Thalidomide and its Analogues

Reinaldo Compagnone, Michael Mijares, Juan Sanctis

Recent Patents on Inflammation & Allergy Drug Discovery, 2010

View PDFchevron_right

Thalidomide: An experience in therapeutic outcome and adverse reactions

Vikram Mahajan

Journal of Dermatological Treatment, 2007

View PDFchevron_right

Thalidomide and its analogs

Hamza Mujagic

View PDFchevron_right

Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients

Francisco Chung

Clinical Cancer Research, 2004

View PDFchevron_right

Recent advances in analytical determination of thalidomide and its metabolites

Catalina Martina Espinosa

Journal of Pharmaceutical and Biomedical Analysis, 2008

View PDFchevron_right

Thalidomide in Oncology: The Peril and the Promise

Rod Quilitz

Cancer control : journal of the Moffitt Cancer Center, 1999

View PDFchevron_right

Thalidomide and Its Analogs as Anticancer Agents

ChunTa Lab

View PDFchevron_right

Mechanisms of action and potential therapeutic uses of thalidomide

Hamza Mujagic

Croatian medical journal, 2002

View PDFchevron_right

Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug

tze-chen hsieh

Current Medicinal Chemistry, 2013

View PDFchevron_right

Thalidomide: A Banned Drug Resurged into Future Anticancer Drug

Wani Waseem

Current Drug Therapy, 2012

View PDFchevron_right

Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses

Ken Washenik

Journal of the American Academy of Dermatology, 1996

View PDFchevron_right

Thalidomide: from tragedy to promise

Roger Von Moos

Swiss Medical Weekly, 2003

View PDFchevron_right

Clinical Trials of Drug – Thalidomide, and Its Derivatives

esaim fadhel khalfa

chemistry and materials research, 2017

View PDFchevron_right

Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide

Paul Ho

Current Drug Metabolism, 2006

View PDFchevron_right

Hydrogen bond and other descriptors for thalidomide and its N-alkyl analogs; prediction of physicochemical and biological properties

Michael Abraham

European Journal of Pharmaceutical Sciences, 2004

View PDFchevron_right

Hydrogen bond and other descriptors for thalidomide and its N-alkyl analogues: prediction of physicochemical and biological properties

Michael Abraham

Eur J Pharm Sci 21 465 469, 2004

View PDFchevron_right

Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer

Anna Cancela, Luciane Di Leone, Sabrina Alves Fernandes

Investigational New Drugs, 2003

View PDFchevron_right

Adverse effects of thalidomide administration in patients with neoplastic diseases

Trajan Balkanov

The American Journal of Medicine, 2004

View PDFchevron_right

High Anti-Inflammatory Activity and Low Toxicity of Thalidomide Analogs

Rodolfo Toledo Filgueiras

Medicinal Chemistry, 2015

View PDFchevron_right

Mono- and Dihydroxylated Metabolites of Thalidomide: Synthesis and TNF-.ALPHA. Production-Inhibitory Activity

Rishav Raj

Chemical and Pharmaceutical Bulletin, 2006

View PDFchevron_right

Thalidomide Therapy:An Open Trial

B. Naafs

International Journal of Dermatology, 2007

View PDFchevron_right

Thalidomide Analogues as Anticancer Drugs

William Figg

Recent Patents on Anti-Cancer Drug Discovery, 2007

View PDFchevron_right

Physicochemical Characterization and Solubility Analysis of Thalidomide and Its N-Alkyl Analogs

Jeanetta Du Plessis, Dr. ritesh bathe

Pharmaceutical Research, 2002

View PDFchevron_right

Development, validation and application of a sensitive LC–MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium

Robert OConnor

Journal of Chromatography B, 2012

View PDFchevron_right

Thalidomide for treatment of multiple myeloma: 10 years later

Anders Waage

Blood, 2008

View PDFchevron_right

The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development

Hillard M Lazarus

Therapeutic advances in hematology, 2011

View PDFchevron_right

Thalidomide analogs and PDE4 inhibition

Laura G. Corral

Bioorganic & Medicinal Chemistry Letters, 1998

View PDFchevron_right

Enantioselective inhibition of TNF? release by thalidomide and thalidomide-analogues

Kai Zwingenberger

Chirality, 1996

View PDFchevron_right

Pharmacokinetics of thalidomide in an elderly prostate cancer population

Alice Chen

Journal of Pharmaceutical Sciences, 1999

View PDFchevron_right

Immunomodulation by thalidomide and thalidomide analogues

Laura G. Corral

Annals of the rheumatic diseases, 1999

View PDFchevron_right

Neuroprotective effect of thalidomide on MPTP-induced toxicity

Guadalupe Palencia

NeuroToxicology, 2015

View PDFchevron_right

Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis

George Kaysen

Journal of Pharmacy and Pharmacology, 2003

View PDFchevron_right